Relapse patterns in FIGO stage IB carcinoma of the cervix.
Site of recurrence and survival data were reviewed for 96 patients with FIGO stage IB cervical carcinoma treated between July 1978 and December 1986 with radical surgery (N = 55), radiation therapy (N = 30), or combination therapy (N = 11). There were 21 patients (21.8%) who suffered recurrences. After radiation 10 of 30 (33.3%) patients recurred versus 11 of 55 (20%) after radical surgery alone. Recurrences were observed in 6 of 14 (42.8%) patients with positive nodes, 11 of 61 (18%) patients with negative nodes, and 4 of 21 (19%) patients with unknown nodal status. The first manifestation of recurrence was central in 3, locoregional in 9, and distant in 9. The median disease-free interval (DFI) was 11 months for surgical and 10.5 months for irradiated patients. The 2-year disease-free survival was 83.6% for surgical patients and 73.3% for irradiated patients. The risk of distant metastases was 3 of 55 (5.4%) following radical surgery and 6 of 30 (20%) after radiation (P = 0.04). The median time to pelvic recurrence was 10 months and that for distant recurrence was 20 months (P less than 0.05). The median time to pelvic relapse was 9.5 months for radical surgery patients and 10 months for irradiated patients. The median time to distant recurrence was 20 months for radical surgery patients and 16.5 months for irradiated patients. Median survival in those who died of disease after a recurrence confined to the pelvis was 15 months versus 8 months for those with a distant recurrence (P less than 0.05). Our data confirm that (1) site of relapse is influenced by primary therapeutic modality and (2) pelvic recurrence manifests before distant recurrence; however, median DFI for all recurrences as well as for the subsets of pelvic and distant relapses is independent of primary modality. We suggest that an understanding of the natural history of cervical cancer recurrence will allow optimal use of resources in the follow-up of patients to detect recurrence.
Look
K Y
KY
Indiana University Medical Center, Indianapolis 46202.
Rocereto
T F
TF
D000230:Adenocarcinoma / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008197:Lymph Node Excision; D009364:Neoplasm Recurrence, Local; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy